Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis.
Antibiotics
Hospitalization
Inflammation
Utilization
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
15
04
2020
revised:
13
06
2020
accepted:
15
06
2020
pubmed:
26
6
2020
medline:
10
9
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
Acute pouchitis is the most common non-surgical complication after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). We used validated case-finding definitions for pouchitis to search administrative claims data and determine the incidence of pouchitis in the first 2 years after IPAA. We identified all patients who underwent proctocolectomy with IPAA for UC in the IQVIA Legacy PharMetrics Adjudicated Claims Database, from January 1, 2007 through June 1, 2016. The primary outcome was the development of pouchitis within 2 years after IPAA. Secondary outcomes included isolated acute vs recurrent pouchitis, immunosuppressive therapy, further surgery, and admission to the hospital. Among 594 patients, the cumulative incidence of pouchitis within 2 years of IPAA was 48% (95% CI, 44%-52%). The cumulative incidence of isolated acute pouchitis was 29% (95% CI, 26%-33%). Compared to patients with isolated acute pouchitis, patients who received a diagnosis of recurrent pouchitis (cumulative incidence, 19%: 95% CI, 16%-22%) demonstrated increased outpatient visits, emergency department visits, and inpatient admissions (all P < .001). Patients who developed pouchitis were more likely to have a history of primary sclerosing cholangitis (adjusted odds ratio [aOR], 3.94; 95% CI, 1.05-14.8) and anti-tumor necrosis factor alpha therapy prior to colectomy (aOR 1.63; 95% CI, 1.09-2.45). Among patients with pouchitis, the cumulative frequency of new immunosuppressive therapy was 40% (95% CI, 35%-46%) and the cumulative incidence of pouch excision was 1.0% (95% CI, 0.4%-3.0%). The cumulative incidence of a new diagnosis of Crohn's disease after IPAA for UC was 9.0% (95% CI, 7.2%-11%). In a geographically diverse population, 48% of patients with UC developed pouchitis within the first 2 years after IPAA. Patients with pouchitis had greater use of healthcare resources, indicating a significant burden of disease.
Sections du résumé
BACKGROUND & AIMS
Acute pouchitis is the most common non-surgical complication after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). We used validated case-finding definitions for pouchitis to search administrative claims data and determine the incidence of pouchitis in the first 2 years after IPAA.
METHODS
We identified all patients who underwent proctocolectomy with IPAA for UC in the IQVIA Legacy PharMetrics Adjudicated Claims Database, from January 1, 2007 through June 1, 2016. The primary outcome was the development of pouchitis within 2 years after IPAA. Secondary outcomes included isolated acute vs recurrent pouchitis, immunosuppressive therapy, further surgery, and admission to the hospital.
RESULTS
Among 594 patients, the cumulative incidence of pouchitis within 2 years of IPAA was 48% (95% CI, 44%-52%). The cumulative incidence of isolated acute pouchitis was 29% (95% CI, 26%-33%). Compared to patients with isolated acute pouchitis, patients who received a diagnosis of recurrent pouchitis (cumulative incidence, 19%: 95% CI, 16%-22%) demonstrated increased outpatient visits, emergency department visits, and inpatient admissions (all P < .001). Patients who developed pouchitis were more likely to have a history of primary sclerosing cholangitis (adjusted odds ratio [aOR], 3.94; 95% CI, 1.05-14.8) and anti-tumor necrosis factor alpha therapy prior to colectomy (aOR 1.63; 95% CI, 1.09-2.45). Among patients with pouchitis, the cumulative frequency of new immunosuppressive therapy was 40% (95% CI, 35%-46%) and the cumulative incidence of pouch excision was 1.0% (95% CI, 0.4%-3.0%). The cumulative incidence of a new diagnosis of Crohn's disease after IPAA for UC was 9.0% (95% CI, 7.2%-11%).
CONCLUSIONS
In a geographically diverse population, 48% of patients with UC developed pouchitis within the first 2 years after IPAA. Patients with pouchitis had greater use of healthcare resources, indicating a significant burden of disease.
Identifiants
pubmed: 32585362
pii: S1542-3565(20)30846-6
doi: 10.1016/j.cgh.2020.06.035
pmc: PMC8552292
mid: NIHMS1606372
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1583-1591.e4Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK034987
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Inflamm Bowel Dis. 2014 Feb;20(2):398-415
pubmed: 24280882
Clin Gastroenterol Hepatol. 2021 Apr;19(4):842-844.e1
pubmed: 32147595
Aliment Pharmacol Ther. 2017 Mar;45(5):581-592
pubmed: 28008631
J R Coll Surg Edinb. 2001 Dec;46(6):334-7
pubmed: 11768572
Clin Gastroenterol Hepatol. 2006 Jan;4(1):81-9; quiz 2-3
pubmed: 16431309
Ann Surg. 2013 Apr;257(4):679-85
pubmed: 23299522
Am J Epidemiol. 1999 May 15;149(10):916-24
pubmed: 10342800
Gastroenterology. 2019 Apr;156(5):1345-1353.e4
pubmed: 30639677
Inflamm Bowel Dis. 2017 Jul;23(7):1218-1224
pubmed: 28426474
Clin Gastroenterol Hepatol. 2008 May;6(5):561-8
pubmed: 18378498
Aliment Pharmacol Ther. 2016 May;43(9):994-1003
pubmed: 26991059
Gastroenterology. 2020 Feb;158(3):610-624.e13
pubmed: 31605691
Inflamm Bowel Dis. 2017 May;23(5):781-790
pubmed: 28301429
Clin Gastroenterol Hepatol. 2020 May;18(6):1356-1366
pubmed: 31589972
Clin Gastroenterol Hepatol. 2007 Aug;5(8):952-8; quiz 887
pubmed: 17544871
Aliment Pharmacol Ther. 2013 May;37(9):867-75
pubmed: 23480145
Dis Colon Rectum. 2019 Nov;62(11):1344-1351
pubmed: 31596761
Crohns Colitis 360. 2019 Oct;1(3):otz029
pubmed: 31667470
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9
pubmed: 17904915
Aliment Pharmacol Ther. 2017 Sep;46(5):508-515
pubmed: 28664992
Nat Rev Gastroenterol Hepatol. 2012 Apr 17;9(6):323-33
pubmed: 22508158
Gastroenterology. 2003 May;124(5):1202-9
pubmed: 12730861
Inflamm Bowel Dis. 2020 Jun 18;26(7):1079-1086
pubmed: 31587035
Inflamm Bowel Dis. 2019 Aug 20;25(9):1474-1480
pubmed: 30698715
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1538-49
pubmed: 23602818
Gastroenterology. 2012 Aug;143(2):390-399.e1
pubmed: 22584081